<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font17 { font-size : 17; } .font20 { font-size : 20; } .font21 { font-size : 21; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font21">the </span>
   <span class="font20">with </span>
   <span class="font17">for </span>
   <span class="font15">HIV </span>
   <span class="font13">patients </span>
   <span class="font13">tuberculosis </span>
   <span class="font13">are </span>
   <span class="font13">treatment </span>
   <span class="font13">The </span>
   <span class="font13">drugs </span>
   <span class="font13">should </span>
   <span class="font12">al. </span>
   <span class="font12">;():â€". </span>
   <span class="font12">drug </span>
   <span class="font12">ART </span>
   <span class="font12">M/XDR-TB </span>
   <span class="font12">resistance </span>
   <span class="font12">from </span>
   <span class="font12">anti-TB </span>
   <span class="font12">regimens </span>
   <span class="font12">have </span>
   <span class="font11">can </span>
   <span class="font11">among </span>
   <span class="font11">has </span>
   <span class="font11">been </span>
   <span class="font11">Bdq </span>
   <span class="font11">months): </span>
   <span class="font11">regimen </span>
   <span class="font11">risk </span>
   <span class="font11">such </span>
   <span class="font11">Dis. </span>
   <span class="font11">not </span>
   <span class="font11">DR-TB </span>
   <span class="font11">also </span>
   <span class="font11">infection </span>
   <span class="font11">{background </span>
   <span class="font11">MDR-TB </span>
   <span class="font11">PLHIV </span>
   <span class="font11">Lzd </span>
   <span class="font11">Mfx </span>
   <span class="font11">high </span>
   <span class="font11">reported </span>
   <span class="font11">Cfz </span>
   <span class="font11">Lfx </span>
   <span class="font11">may </span>
   <span class="font11">that </span>
   <span class="font11">therapy </span>
   <span class="font11">all </span>
   <span class="font11">drug-resistant </span>
   <span class="font11">second-line </span>
   <span class="font11">Pto </span>
   <span class="font11">used </span>
   <span class="font11">â—� </span>
   <span class="font11">Eto </span>
   <span class="font11">antiretroviral </span>
   <span class="font11">margin </span>
   <span class="font11">â€" </span>
   <span class="font10">Efv </span>
   <span class="font10">WHO </span>
   <span class="font10">both </span>
   <span class="font10">burden </span>
   <span class="font10">cases </span>
   <span class="font10">coinfection. </span>
   <span class="font10">more </span>
   <span class="font10">{border-style </span>
   <span class="font10">diagnosis </span>
   <span class="font10">one </span>
   <span class="font10">recommended </span>
   <span class="font10">was </span>
   <span class="font10">HIV-infected </span>
   <span class="font10">Med. </span>
   <span class="font10">management </span>
   <span class="font10">multidrug-resistant </span>
   <span class="font10">other </span>
   <span class="font10">px;} </span>
   <span class="font10">these </span>
   <span class="font10">two </span>
   <span class="font10">#ffffff;} </span>
   <span class="font10">patient </span>
   <span class="font10">poor </span>
   <span class="font10">responsible </span>
   <span class="font10">Group </span>
   <span class="font10">between </span>
   <span class="font10">clinical </span>
   <span class="font10">outcomes </span>
   <span class="font10">three </span>
   <span class="font10">when </span>
   <span class="font10">(inhibitor); </span>
   <span class="font10">ADRs </span>
   <span class="font10">Infect </span>
   <span class="font10">Int </span>
   <span class="font10">Lung </span>
   <span class="font10">Tuberc </span>
   <span class="font10">cause </span>
   <span class="font10">containing </span>
   <span class="font10">diagnostic </span>
   <span class="font10">including </span>
   <span class="font10">increased </span>
   <span class="font10">mortality </span>
   <span class="font10">particularly </span>
   <span class="font10">were </span>
   <span class="font10">which </span>
   <span class="font10">without </span>
   <span class="font10">.collab: </span>
   <span class="font10">;():e. </span>
   <span class="font10">Accessed </span>
   <span class="font10">Dlm </span>
   <span class="font10">Nvp </span>
   <span class="font10">PLoS </span>
   <span class="font10">South </span>
   <span class="font10">Treatment </span>
   <span class="font10">Tzd </span>
   <span class="font10">cannot </span>
   <span class="font10">coinfection </span>
   <span class="font10">especially </span>
   <span class="font10">overlapping </span>
   <span class="font10">transmission </span>
   <span class="font10">FTC </span>
   <span class="font10">but </span>
   <span class="font10">disease </span>
   <span class="font10">due </span>
   <span class="font10">first-line </span>
   <span class="font10">systematic </span>
   <span class="font10">there </span>
   <span class="font10">this </span>
   <span class="font10">drugs, </span>
   <span class="font10">factors </span>
   <span class="font10">high-dose </span>
   <span class="font10">interactions </span>
   <span class="font10">leading </span>
   <span class="font10">newer </span>
   <span class="font10">potential </span>
   <span class="font10">reduce </span>
   <span class="font10">remains </span>
   <span class="font10">shorter </span>
   <span class="font10">than </span>
   <span class="font10">tuberculosis: </span>
   <span class="font10">use </span>
   <span class="font10">used, </span>
   <span class="font10">(inducer); </span>
   <span class="font10">(â€" </span>
   <span class="font10">Cfz, </span>
   <span class="font10">DST </span>
   <span class="font10">Health </span>
   <span class="font10">TDF </span>
   <span class="font10">This </span>
   <span class="font10">active </span>
   <span class="font10">additional </span>
   <span class="font10">associated </span>
   <span class="font10">countries </span>
   <span class="font10">even </span>
   <span class="font10">higher </span>
   <span class="font10">least </span>
   <span class="font10">monitoring </span>
   <span class="font10">patients, </span>
   <span class="font10">people </span>
   <span class="font10">preferred </span>
   <span class="font10">rapid </span>
   <span class="font10">review </span>
   <span class="font10">therapy. </span>
   <span class="font10">Azt </span>
   <span class="font10">Geneva: </span>
   <span class="font10">Lzd, </span>
   <span class="font10">Mfx, </span>
   <span class="font10">Table </span>
   <span class="font10">These </span>
   <span class="font10">World </span>
   <span class="font10">contains </span>
   <span class="font10">doi:./S-()- </span>
   <span class="font10">extensively </span>
   <span class="font10">genotypic </span>
   <span class="font10">include </span>
   <span class="font10">infection. </span>
   <span class="font10">months </span>
   <span class="font10">prevalence </span>
   <span class="font10">pulmonary </span>
   <span class="font10">rates </span>
   <span class="font10">regarding </span>
   <span class="font10">replace </span>
   <span class="font10">resistant </span>
   <span class="font10">strategy </span>
   <span class="font10">study </span>
   <span class="font10">tests, </span>
   <span class="font10">(inhibitor) </span>
   <span class="font10">ART, </span>
   <span class="font10">FQs </span>
   <span class="font10">However, </span>
   <span class="font10">MTB/RIF </span>
   <span class="font10">One. </span>
   <span class="font10">PLHIV, </span>
   <span class="font10">after </span>
   <span class="font10">appropriate </span>
   <span class="font10">case </span>
   <span class="font10">culture </span>
   <span class="font10">data </span>
   <span class="font10">doi:./journal.pone. </span>
   <span class="font10">followed </span>
   <span class="font10">global </span>
   <span class="font10">group </span>
   <span class="font10">incidence </span>
   <span class="font10">initiation </span>
   <span class="font10">observed </span>
   <span class="font10">significant </span>
   <span class="font10">treatment. </span>
   <span class="font10">Abc </span>
   <span class="font10">African </span>
   <span class="font10">All </span>
   <span class="font10">Anti-TB </span>
   <span class="font10">CBNAAT </span>
   <span class="font10">HIV-associated </span>
   <span class="font10">M/XDR-TB. </span>
   <span class="font10">Mycobacterium </span>
   <span class="font10">Regimen </span>
   <span class="font10">There </span>
   <span class="font10">adherence </span>
   <span class="font10">adults </span>
   <span class="font10">advanced </span>
   <span class="font10">adverse </span>
   <span class="font10">agent </span>
   <span class="font10">agents </span>
   <span class="font10">based </span>
   <span class="font10">chemoprophylaxis </span>
   <span class="font10">control </span>
   <span class="font10">either </span>
   <span class="font10">extrapulmonary </span>
   <span class="font10">further </span>
   <span class="font10">given </span>
   <span class="font10">inhibitors </span>
   <span class="font10">integrase </span>
   <span class="font10">lack </span>
   <span class="font10">living </span>
   <span class="font10">medications </span>
   <span class="font10">only </span>
   <span class="font10">over </span>
   <span class="font10">px; </span>
   <span class="font10">rate </span>
   <span class="font10">receiving </span>
   <span class="font10">results </span>
   <span class="font10">settings </span>
   <span class="font10">trials </span>
   <span class="font10">tuberculosis. </span>
   <span class="font10">{font-family </span>
   <span class="font10">;:â€". </span>
   <span class="font10">Available </span>
   <span class="font10">Drugs </span>
   <span class="font10">Eto/Pto, </span>
   <span class="font10">GeneXpert </span>
   <span class="font10">HIV. </span>
   <span class="font10">Lfx, </span>
   <span class="font10">New </span>
   <span class="font10">Ptm </span>
   <span class="font10">Therefore, </span>
   <span class="font10">WHO; </span>
   <span class="font10">activities </span>
   <span class="font10">association </span>
   <span class="font10">combination </span>
   <span class="font10">common </span>
   <span class="font10">component </span>
   <span class="font10">components </span>
   <span class="font10">consider </span>
   <span class="font10">conventional </span>
   <span class="font10">documented </span>
   <span class="font10">drugs. </span>
   <span class="font10">effective </span>
   <span class="font10">efficacy </span>
   <span class="font10">epidemics </span>
   <span class="font10">essential </span>
   <span class="font10">existing </span>
   <span class="font10">font-size </span>
   <span class="font10">forms </span>
   <span class="font10">health </span>
   <span class="font10">high-risk </span>
   <span class="font10">important </span>
   <span class="font10">improve </span>
   <span class="font10">latent </span>
   <span class="font10">measures </span>
   <span class="font10">months: </span>
   <span class="font10">out </span>
   <span class="font10">patients. </span>
   <span class="font10">programmatic </span>
   <span class="font10">programs </span>
   <span class="font10">progression </span>
   <span class="font10">replacement </span>
   <span class="font10">resource-limited </span>
   <span class="font10">result </span>
   <span class="font10">shown </span>
   <span class="font10">surveillance </span>
   <span class="font10">those </span>
   <span class="font10">years </span>
   <span class="font10">AIDS </span>
   <span class="font10">AIDS. </span>
   <span class="font10">Also </span>
   <span class="font10">CYPA </span>
   <span class="font10">DS-TB </span>
   <span class="font10">Engl </span>
   <span class="font10">HIV-positive </span>
   <span class="font10">Lancet </span>
   <span class="font10">Organization. </span>
   <span class="font10">Other </span>
   <span class="font10">PIs </span>
   <span class="font10">Patients </span>
   <span class="font10">TB. </span>
   <span class="font10">Tuberculosis </span>
   <span class="font10">Various </span>
   <span class="font10">additive </span>
   <span class="font10">adequate </span>
   <span class="font10">any </span>
   <span class="font10">because </span>
   <span class="font10">co-infected </span>
   <span class="font10">coinfection, </span>
   <span class="font10">compared </span>
   <span class="font10">count </span>
   <span class="font10">diagnosis, </span>
   <span class="font10">disease. </span>
   <span class="font10">double; </span>
   <span class="font10">drugâ€"drug </span>
   <span class="font10">during </span>
   <span class="font10">early </span>
   <span class="font10">evidence </span>
   <span class="font10">guidelines </span>
   <span class="font10">immunodeficiency </span>
   <span class="font10">levels </span>
   <span class="font10">meta-analysis </span>
   <span class="font10">meta-analysis. </span>
   <span class="font10">opportunistic </span>
   <span class="font10">oral </span>
   <span class="font10">preference </span>
   <span class="font10">preventive </span>
   <span class="font10">probability </span>
   <span class="font10">reactions </span>
   <span class="font10">required </span>
   <span class="font10">resistance. </span>
   <span class="font10">settings. </span>
   <span class="font10">showing </span>
   <span class="font10">study. </span>
   <span class="font10">testing </span>
   <span class="font10">their </span>
   <span class="font10">toxicity </span>
   <span class="font10">treated </span>
   <span class="font10">well </span>
   <span class="font10">â€". </span>
   <span class="font10">(major/inhibitor); </span>
   <span class="font10">ART. </span>
   <span class="font10">Africa </span>
   <span class="font10">Africa. </span>
   <span class="font10">Antiretroviral </span>
   <span class="font10">Azt, </span>
   <span class="font10">Bdq, </span>
   <span class="font10">Children </span>
   <span class="font10">Clin </span>
   <span class="font10">Clinical </span>
   <span class="font10">Cs, </span>
   <span class="font10">DR-TB. </span>
   <span class="font10">DT, </span>
   <span class="font10">Drug-resistant </span>
   <span class="font10">Dtg </span>
   <span class="font10">Eto/Pto </span>
   <span class="font10">Guidelines </span>
   <span class="font10">High </span>
   <span class="font10">IRIS </span>
   <span class="font10">LiPAs </span>
   <span class="font10">Lpv/r </span>
   <span class="font10">PAS, </span>
   <span class="font10">PIs, </span>
   <span class="font10">TB/HIV </span>
   <span class="font10">Therapy </span>
   <span class="font10">WHO. </span>
   <span class="font10">XDR-TB </span>
   <span class="font10">Xpert </span>
   <span class="font10">acquired </span>
   <span class="font10">although </span>
   <span class="font10">analysis </span>
   <span class="font10">baseline </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">burden, </span>
   <span class="font10">cases. </span>
   <span class="font10">causes </span>
   <span class="font10">challenging </span>
   <span class="font10">coinfected </span>
   <span class="font10">community </span>
   <span class="font10">considered </span>
   <span class="font10">contacts </span>
   <span class="font10">cure </span>
   <span class="font10">ddI, </span>
   <span class="font10">detected </span>
   <span class="font10">detection </span>
   <span class="font10">developing </span>
   <span class="font10">different </span>
   <span class="font10">difficult </span>
   <span class="font10">doi:./journal.pmed. </span>
   <span class="font10">emergence </span>
   <span class="font10">failure </span>
   <span class="font10">first </span>
   <span class="font10">frequently </span>
   <span class="font10">high-burden </span>
   <span class="font10">high. </span>
   <span class="font10">human </span>
   <span class="font10">implementation </span>
   <span class="font10">infected </span>
   <span class="font10">inhibitor </span>
   <span class="font10">initial </span>
   <span class="font10">laboratory </span>
   <span class="font10">larger </span>
   <span class="font10">low </span>
   <span class="font10">metabolized </span>
   <span class="font10">multiple </span>
   <span class="font10">near </span>
   <span class="font10">new </span>
   <span class="font10">outcomes. </span>
   <span class="font10">pain </span>
   <span class="font10">pill </span>
   <span class="font10">population </span>
   <span class="font10">prospective </span>
   <span class="font10">reduction </span>
   <span class="font10">regimens, </span>
   <span class="font10">region </span>
   <span class="font10">rifampicin </span>
   <span class="font10">routine </span>
   <span class="font10">sequence </span>
   <span class="font10">sequencing </span>
   <span class="font10">show </span>
   <span class="font10">solid; </span>
   <span class="font10">started </span>
   <span class="font10">studies </span>
   <span class="font10">sub-Saharan </span>
   <span class="font10">tests </span>
   <span class="font10">therapy, </span>
   <span class="font10">toxicities </span>
   <span class="font10">under </span>
   <span class="font10">usually </span>
   <span class="font10">various </span>
   <span class="font10">very </span>
   <span class="font10">where </span>
   <span class="font10">while </span>
   <span class="font10">who </span>
   <span class="font10">will </span>
   <span class="font10">work </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">&amp;lt; </span>
   <span class="font10">;:. </span>
   <span class="font10">ADRs, </span>
   <span class="font10">ADRs. </span>
   <span class="font10">Africa: </span>
   <span class="font10">Am, </span>
   <span class="font10">BMC </span>
   <span class="font10">CYP </span>
   <span class="font10">Cm, </span>
   <span class="font10">Delhi, </span>
   <span class="font10">Department </span>
   <span class="font10">Drug </span>
   <span class="font10">Efv, </span>
   <span class="font10">European </span>
   <span class="font10">Global </span>
   <span class="font10">HIV-negative </span>
   <span class="font10">India. </span>
   <span class="font10">Km, </span>
   <span class="font10">Lancet. </span>
   <span class="font10">M/XDR-TB, </span>
   <span class="font10">Medical </span>
   <span class="font10">Medicine, </span>
   <span class="font10">Nvp, </span>
   <span class="font10">Ofx, </span>
   <span class="font10">Prompt </span>
   <span class="font10">Pulmonary </span>
   <span class="font10">Regimens </span>
   <span class="font10">Respir </span>
   <span class="font10">SLIDs </span>
   <span class="font10">SLIDs, </span>
   <span class="font10">Shorter </span>
   <span class="font10">TB, </span>
   <span class="font10">Tmp-Smx </span>
   <span class="font10">WGS </span>
   <span class="font10">acidosis </span>
   <span class="font10">addition </span>
   <span class="font10">adopted </span>
   <span class="font10">age </span>
   <span class="font10">antitubercular </span>
   <span class="font10">apart </span>
   <span class="font10">approach </span>
   <span class="font10">available </span>
   <span class="font10">avoided </span>
   <span class="font10">before </span>
   <span class="font10">bold </span>
   <span class="font10">care </span>
   <span class="font10">certain </span>
   <span class="font10">children. </span>
   <span class="font10">co-infection </span>
   <span class="font10">coadministered </span>
   <span class="font10">collaborative </span>
   <span class="font10">concomitant </span>
   <span class="font10">contact </span>
   <span class="font10">could </span>
   <span class="font10">countries. </span>
   <span class="font10">courier; </span>
   <span class="font10">currently </span>
   <span class="font10">death </span>
   <span class="font10">decreased </span>
   <span class="font10">defined </span>
   <span class="font10">detect </span>
   <span class="font10">determined </span>
   <span class="font10">disease, </span>
   <span class="font10">doi:./ </span>
   <span class="font10">doi:./ijtld.. </span>
   <span class="font10">duration </span>
   <span class="font10">em; </span>
   <span class="font10">end </span>
   <span class="font10">enhancing </span>
   <span class="font10">evolution </span>
   <span class="font10">frequent </span>
   <span class="font10">general </span>
   <span class="font10">groups, </span>
   <span class="font10">hepatitis </span>
   <span class="font10">highly </span>
   <span class="font10">history </span>
   <span class="font10">impact </span>
   <span class="font10">index </span>
   <span class="font10">indicated </span>
   <span class="font10">individualized </span>
   <span class="font10">infection-control </span>
   <span class="font10">inflammatory </span>
   <span class="font10">inhibitors, </span>
   <span class="font10">intense </span>
   <span class="font10">interaction </span>
   <span class="font10">interactions. </span>
   <span class="font10">involving </span>
   <span class="font10">lactic </span>
   <span class="font10">last </span>
   <span class="font10">less </span>
   <span class="font10">level </span>
   <span class="font10">likely </span>
   <span class="font10">local </span>
   <span class="font10">major </span>
   <span class="font10">majority </span>
   <span class="font10">maraviroc </span>
   <span class="font10">mg/day </span>
   <span class="font10">million </span>
   <span class="font10">mortality. </span>
   <span class="font10">must </span>
   <span class="font10">needs </span>
   <span class="font10">number </span>
   <span class="font10">often </span>
   <span class="font10">ones. </span>
   <span class="font10">ongoing </span>
   <span class="font10">order </span>
   <span class="font10">paradoxical </span>
   <span class="font10">patterns </span>
   <span class="font10">phase </span>
   <span class="font10">phenotypic </span>
   <span class="font10">possible </span>
   <span class="font10">preventing </span>
   <span class="font10">prevention </span>
   <span class="font10">primary </span>
   <span class="font10">prompt </span>
   <span class="font10">pt;} </span>
   <span class="font10">quality </span>
   <span class="font10">rash </span>
   <span class="font10">recommendations </span>
   <span class="font10">regions </span>
   <span class="font10">remain </span>
   <span class="font10">renal </span>
   <span class="font10">research </span>
   <span class="font10">resistance, </span>
   <span class="font10">resulting </span>
   <span class="font10">retreatment </span>
   <span class="font10">reverse-transcriptase </span>
   <span class="font10">rule </span>
   <span class="font10">similar </span>
   <span class="font10">skin </span>
   <span class="font10">smear-negative </span>
   <span class="font10">standardized </span>
   <span class="font10">strain </span>
   <span class="font10">strong </span>
   <span class="font10">susceptibility </span>
   <span class="font10">switching </span>
   <span class="font10">syndrome </span>
   <span class="font10">test </span>
   <span class="font10">treatment, </span>
   <span class="font10">unfavorable </span>
   <span class="font10">universal </span>
   <span class="font10">using </span>
   <span class="font10">vomiting </span>
   <span class="font10">whether </span>
   <span class="font10">within </span>
   <span class="font10">worsening </span>
  </p>
 </body>
</html>
